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Abstract: Cigarette smoke (CS), a complex chemical mixture, contains more than 4,800 
different compounds, including oxidants, heavy metals, and carcinogens, that individually 
or in combination initiate or promote pathogenesis in the lung accounting for 82% of 
chronic obstructive pulmonary disease (COPD) deaths and 87% of lung cancer deaths. 
Lysyl oxidase (LO), a Cu-dependent enzyme, oxidizes peptidyl lysine residues in collagen, 
elastin and histone H1, essential for stabilization of the extracellular matrix and cell 
nucleus. Considerable evidences have shown that LO is a tumor suppressor as exemplified 
by inhibiting transforming activity of ras,  a proto oncogene. CS condensate (CSC),   
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and cadmium (Cd), major 
components of CS, down-regulate LO expression at such multiple levels as mRNA, protein 
and catalytic activity in lung cells in vitro and in vivo indicating LO as a critical intra- and 
extracellular target for CS pathogenesis in the lung. In view of multiple biological 
functions and regulation characteristics of the LO gene, molecular mechanisms for CS 
damage to lung LO and its role in emphysema and cancer pathogenesis are discussed in 
this review. 
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1. Introduction  
 
Cigarette smoke (CS) is one of the most important risk factors for human disease, accounting   
for 82% of chronic obstructive pulmonary disease (COPD) deaths and 87% of lung cancer deaths [1-4]. 
Approximately 23% of the US adults currently smoke because of addiction to nicotine, an important 
component of CS. More than 440,000 Americans and approximately five million people in the World 
die prematurely each year as a result of tobacco use and tobacco smoke exposure [5]. Cigarettes kill 
more Americans than alcohol, car accidents, suicide, AIDS, homicide and illegal drugs combined [6].  
Long-term exposure of humans to CS usually results in COPD in some people, often manifested as 
bronchitis, emphysema or both. Emphysema is a pathological lesion characterized by abnormal 
enlargement of the respiratory airspaces with destruction of the alveolar walls. Most studies of 
emphysema pathogenesis have focused on the “elastase-antielastase imbalance” hypothesis [7].   
CS-activated macrophages and neutrophils release elastase that proteolyses elastin fibers contributing 
to lung injury [8,9]. However, this hypothesis cannot explain all aspects of the emphysema pathology. 
For example, the CS-induced emphysematous lung in guinea pigs exhibited breakdown of collagen 
without significant changes in elastin [10]. Transgenic mice that over-express the human collagenase 
gene developed early onset emphysema [11]. Thereby, the “elastase-antielastase imbalance” is not the 
only mechanism for emphysema pathogenesis.  
  Strong evidence supports the association of CS with lung cancer. CS is responsible   
for 772,000 and 265,000 new lung cancer cases in men and women, respectively, each year worldwide 
[12]. Passive smoke, also known as sidestream smoke (SS), environmental tobacco smoke (ETS) or 
second-hand smoke, may have more carcinogenic potentials than the mainstream smoke (MS) since it 
contains larger quantities of organic chemical compounds [13]. Cessation of smoking sharply declines 
pulmonary carcinogenesis in ex-smokers after approximately five years since quitting in comparison to 
continuous smokers [12], indicating CS as an important risk factor for lung cancers. Smoke-induced 
lung malignancies are mainly classified as squamous cell carcinoma, small cell carcinoma, 
adenocarcinoma, etc. [12]. Note that in addition to the lung, CS can also act as a critical cancer   
risk factor involved in other organs such as the larynx, bladder, esophagus, pancreas, kidney,   
oral cavity, etc. [12]. In light of its severe insults to the lung and other organs, CS is of a continuing 
human health concern. Thus, it is important and necessary to deeply investigate molecular mechanisms 
and preventing and therapeutic strategies for CS-induced lung diseases.  
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2. Major Pathogenic Agents of CS  
 
2.1. CS, a Complex Chemical Mixture  
CS contains more than 4,800 different compounds, including oxidants, heavy metals, and 
carcinogens, that individually or in combination initiate or promote pathogenesis in the lung [14,15]. 
Each puff of smoke produces 10
14–10
16 free radicals inducing oxidative damage to the lung [16]. The 
mainstream smoke coming from a burning cigarette is composed of a vapor phase (92%) and a 
particulate phase (8%). The major constituents of the vapor phase include carbon monoxide,   
ammonia, nitrogen oxides, hydrogen cyanide, isoprene, butadiene, formaldehyde, acetaldehyde, etc.  
The particulate phase or CS condensate (CSC) contains at least 3,500 compounds. There are   
5 × 10
9 particles/mL with diameters of 0.1–1 m in the mainstream CS aerosol in comparison   
to 10
5/mL aerosol particles with diameters 0.1–>10 m in urban air. Thus, all of the particles in CS are 
within the size range reaching the alveolar space, known to be 0.1–3 m [14]. Although the chemical 
composition of both MS and SS are quantitatively similar they still exhibit significant quantitative 
variety because of the temperature differences at which MS and SS are formed. Inhaled fresh 
sidestream cigarette smoke is approximately four times more toxic per gram total particulate matter 
(TPM) than mainstream cigarette smoke [17]. Based on our research focuses, two important   
classes of toxic/carcinogenic components in CSC such as the nicotine-derived nitrosamines,   
e.g., 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and heavy metals, e.g., cadmium (Cd) 
[14,15] will be discussed in this review.  
2.2. NNK and Cd, Two of Major Pathogenic and Carcinogenic Components of CS 
NNK, a tobacco-specific nicotine-nitrosated derivative, has been demonstrated as a very potent 
carcinogen in rodents, particularly in rats [18]. Its sales-weighted concentration in one current   
“full-flavored cigarette” is 131 ng [19]. The estimated life time exposure to NNK of a cigarette smoker 
is about 1.1 mg/kg. close to the lowest NNK dose (1.8 mg/kg) that induced tumors in rats [18,20]. 
NNK exhibits a remarkable affinity for the lung, resulting in adenoma and adenocarcinoma, 
independently of the route of administration [18]. Metabolic activation of NNK by cytochrome P-450 
(CYP) is required to exert its carcinogenic activity [21]. Although it is established that NNK damages 
DNA via formation of methyl adducts [22,23] and mutation of p53, a tumor suppressor gene [24], the 
intracellular events elicited by CS/NNK and their underlying pathological mechanisms leading to cell 
injury and cancer development remain unclear.  
Cd is a toxic metal without any biological availability. In addition to occupational exposure, 
cigarette smoke constitutes a major source of Cd exposure for humans since tobacco naturally absorbs 
mobile forms of Cd, e.g., CdCl2, CdSO4, Cd(NO3)2, Cd(CH3COO)2, etc., from soil and accumulates 
relatively high concentrations of Cd in the leaves [25,26]. The lung, a major CS-target organ, not only 
absorbs but also accumulates Cd with a biological half-life of 9.4 years [25,27]. Each cigarette 
contains 1–2 g Cd, of which 10% is inhaled [25,26]. Pulmonary Cd levels in smokers reached   
7.5-fold greater than those in non-smokers [28]. Long-term exposure to Cd resulted in emphysema 
[29-31]. Fatal emphysema developed in Cd-poisoned patients who had survived acute lung injuries in Int. J. Environ. Res. Public Health 2011, 8          
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industrial accidents [32]. Clinical correlation studies have established a causal relationship between 
smoking and human emphysema [33]. Smokers with severe emphysema have a high Cd levels in their 
lungs [25,28]. Animal studies indicated that the nature of Cd-induced lung lesions varied with the 
exposure protocols and species used. Both emphysema and fibrosis with and without airspace 
enlargement were produced in rodents [7,34]. Cd was listed by the US Environmental Protection 
Agency as one of 126 priority pollutants [35,36]. Cd is a potent human carcinogen and occupational 
exposure to Cd is associated with cancers in multiple organs such as the lung, the prostate, the 
pancreas, the kidney, etc. Because of its characteristics as a lung carcinogen, Cd was classified as a 
category 1 carcinogen by the International Agency for Research on Cancer (IARC) and the National 
Toxicology Program of the USA [25,36]. Animal studies provide strong evidence for Cd 
carcinogenesis. With the rodent model, mast relevant to human exposure to air-borne Cd, various Cd 
compounds produced adenocarcinomas in the lung of rats after inhalation [37,38]. Due to its negative 
results in bacterial mutagenic tests, Cd is predominantly considered as a non-genotoxic carcinogen 
[25], thus, the mechanism(s) of Cd carcinogenesis remain poorly understood.  
Recent studies by this lab have shown that CSC down-regulates lysyl oxidase (LO), an intra- and 
extracellular enzyme with multiple biological functions, at mRNA, protein and catalytic levels [39-41]. 
This review intends to summarize our current findings indicating LO as a critical intra- and 
extracellular target for CS pathogenesis in the lung.  
 
3. Lysyl Oxidase  
 
3.1. Multiple Functions of LO in Biology 
LO initiates the crosslinking of collagen and elastin by oxidizing specific peptidyl lysine residues in 
these proteins stabilizing collagen or elastin as fibers in the extracellular matrix (ECM) [41]. Thus, LO 
plays a central role in ECM morphogenesis and tissue repair. LO can also oxidize lysine residues in 
various globular proteins with basic isoelectric points (pI > 8), e.g., nuclear proteins histone H1 and H2 
[42,43], bFGF [44], etc., suggesting that electrostatic relationships between the anionic enzyme   
(pI ~ 6.0) and basic protein substrates are critical to substrate potential. In addition to extracellular 
secretion, LO is also localized within the nucleus [45] where it appears to modulate the packing state 
of nuclear chromatin [46]. Labeled 32 kDa mature LO readily enters the intracellular compartments 
and accumulates within the nucleus in vascular smooth muscle cells (VSMC) although mechanistic 
features of its intracellular transport into and through the cytosol are not known [47]. The 32 kDa 
purified LO displays chemotactic activities for monocytes and VSMC [48-50]. LO, as an extracellular 
signal, stimulates stress fiber formation and focal adhesion assembly [50] possibly implicating in 
mechanisms for tumor metastasis in hypoxia conditions [51]. The LO reaction produces H2O2 which 
may regulate gene expression and cell behavior [50]. LO is considered as a tumor suppressor gene 
initiating from the finding that expression of transfected LO cDNA suppressed Ha-ras-induced cell 
transformation indicating a ras-suppressor effect of LO [52]. Our previous studies have demonstrated 
bFGF as a substrate of LO. Oxidation of bFGF by LO blocked the proliferation of bFGF-stimulated 
normal cells and bFGF-autocrine transformed cells with high tumorigenic potential [44]. Based on the  Int. J. Environ. Res. Public Health 2011, 8          
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widening intra- and extracellular distribution of possible substrates of LO, this enzyme may display 
multiple functions in biology beyond its role in stabilization of macromolecules in the ECM. 
3.2. LO Molecular Structure  
As shown in Figures 1A and 1B, LO is synthesized by fibrogenic cells as a 46 kD preproenzyme. 
Following signal peptide cleavage at the CA site (SPCS in Figure 1B) and N-glycosylation at the NRT 
site (GS in Figure 1B), the resulting 50 kD proenzyme is secreted and then proteolytically cleaved at 
the GDD site (PPCS in Figure 1B) to produce the 32 kD functional species in the extracellular space 
[41]. The sequences within the mature enzyme at which the active site (AS in Figure 1B) is located are 
highly conserved (95%) in rat and human (Figure 1B). LO specifically binds 1 g-atom of Cu(II) at its 
active site per mole of enzyme [41]. Five histidine residues located at the sequence of His 283–His 297 
in rat LO (CuBS in Figure 1B) constitute the copper-binding motif. Cu binding to proLO occurs in the 
enzyme secreted pathway such as the Golgi apparatus [53]. In addition to Cu, LO also contains a 
covalently bound carbonyl cofactor identified as lysine tyrosylquinone (LTQ) deriving from Lys 314 
and Tyr 349 (bold letter in Figure 1B) based on the sequence of rat LO [54]. This peptidyl 
orthoquinone functions as a transient electron sink during amine oxidation. The precise role of Cu in 
the LO action remains poorly understood. This metal ion may be essential for maintaining the 
structural integrity of LTQ and/or the protein [41].  
Figure 1. LO synthesis, processing and molecular composition. A , LO synthesis and 
processing. LO synthesis and processing were determined by [
35S]-methionine labeling and 
cycloheximide chase (5 h) assays. 1 and 3, 0 time chase; 2 and 4, 5 h chase; 1 and 2, cell 
extracts; 3 and 4, conditioned media. Note that at 0 time chase the cell extract contains the 
46 kDa prepro-LO, the 50 kDa pro-LO, and the membrane-bound 32 kDa mature LO while 
the conditioned medium contains the secreted 50 kDa pro-LO and the processed 32 kDa 
mature-LO; at 5 h chase all LO species in the cell extract were processed and secreted into 
the extracellular space, and further cleaved to the 32 kD mature enzyme. B, amino acid 
sequences of rat and human LO. SPCS, the signal peptide cleavage site; GS, the   
N-glycosylation site; PPCS, the propeptide cleavage site; AS, the active site; CuBS, the 
copper-binding site; asterisks indicate the different amino acid composition of LO between 
human and rat. 
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Figure 1. Cont. 
 
 
The activity of purified LO can be severely inhibited by metal chelators, e.g., ,’-dipyridyl [55]. 
The reaction with peptidyl lysines catalyzed by LO is: RCH2NH2 + H2O + O2  RCHO + NH3 + H2O2 
[41]. Additional LO-like cDNA species encode a variety of LO-like proteins, including LOXL, 
LOXL2, LOXL3 and LOXL4 [56] which have the homology at the C-terminal domain in comparison 
to the mature LO. Both LO and LO-like proteins at the C-terminal domain contain ten conserved 
cysteine residues, copper binding domains as well as tyrosine and lysine residues for forming the LTQ 
cofactor. Notably, LO also contains a growth factor and cytokine binding domain with the consensus: 
C-x9-10-C-x-W-x26-32-C-x10-15-C (C is Cys, W is Trp, xn is a defined number of any amino acids) found 
in a superfamily of receptors for growth factors and cytokines evolved from fibronectin III sequence 
modules common in cell surface adhesion molecules [56-58].  
 
3.3. LO Gene Core Promoter  
In eukaryotic cells, the gene activation is regulated by the interaction of cis-elements with various 
protein factors at the gene promoter region. The RNA polymerase II (RNA-Poly II) complex binds to 
the core promoter initiating the gene transcription. Comparative LO gene sequence alignment across 
species of rat, human and mouse showed that the proximal promoter region is highly conserved 
whereas the distal promoter region was more divergent among three species suggesting a fundamental 
role of the proximal promoter region in the regulation of LO transcription. The maximal promoter 
activities were detected in the 804, 808 and 924 base pair regions, respectively, immediately upstream 
of ATG in rat, mouse and human LO genes [59]. Thus, the LO transcription control is likely to be 
regulated by similar elements in these species. The 5’-flanking region of the rat LO gene appears to 
contain no typical TATA box, the first core promoter element identified in RNA-Poly II-transcribed 
genes. Multiple transcription start sites cluster in the rat LO promoter region from –78 to –51 relative 
to ATG, one of which overlaps with the adenosine residue of the INR element (5’-TCATTTTT-3’) 
mapped from –53 to –46 in the rat LO promoter [60,61]. Furthermore, the sequence from –18 to –14,  Int. J. Environ. Res. Public Health 2011, 8          
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i.e., 5’-GGACG-3’, a consensus sequence of the DPE that is located approximately 30 bp after the 
adenosine residue in the INR motif [61]. The INR and the DPE conserved in rat, human and mouse 
species coordinately function as a single core promoter unit for the RNA-Poly II-directed gene 
transcription [61]. It should be noted that the DPE in the rat LO gene promoter also worked as an 
independent core promoter module playing a key role in transactivation of the TATA-less LO gene at 
multiple transcription starts sites [59].  
3.4. Redox-sensitive Cis-elements—the NFI-binding Site, HRE, MRE and ARE in the LO Promoter 
Other transcription factor binding sites (cis-acting elements) are generally located upstream of the 
core promoter and act through binding of different transcriptional activators and/or repressors to alter 
the level of gene transcription. In addition to putative binding sites for the following transcription 
factors such as nuclear factor I (NFI), SP1, Oct-1, C/EBP, etc., the cloned rat LO promoter also 
contains the hypoxia response element (HRE), the metal response element (MRE) and antioxidant 
response element (ARE), etc. [59]. The cloned rat LO promoter –804/–1 yielding the maximal 
promoter activity contains three putative NFI-binding sites [59]. NFI binds to the consensus sequence 
TTGGC(N5)GCCAA (N = any nucleotides) on duplex DNA as a dimer. Notably, it can also bind to 
the individual half site, TTGGC or GCCAA, with a somewhat reduced affinity [62]. The highly 
conserved N-terminal residues of NFI contain the DNA binding domain whereas the proline-rich   
C-terminal residues constitute the transcriptional regulation domain [62]. Four cysteine residues are 
conserved in the DNA binding domain of all rat NFI isoforms sensitive to oxidative damage [63,64]. 
In addition, the rat LO promoter region –804/–1 also contains four putative hypoxia response elements 
(HRE, core sequence = RCGTG, R = purine) [65,66] including one on the coding strand and three on 
the noncoding strand at the region –457/–453, –387/–383, –194/–190 and –37/–33 (relative to ATG) 
[59], two putative metal response elements (MRE, core sequence = TGCRCNC, R = purine, N = any 
nucleotide) [67-69] located at –269/–263 and –248/–241, and one antioxidant response element (ARE, 
core sequence = RTGACNNNGC, R = purine, N = any nucleotides) [70] at the region –581/–572 [59]. 
The HIF1 is composed of HIF1 and HIF1 subunits [71]. The HIF1 is constitutively expressed 
whereas HIF1 is maintained at a low level in normoxic cells. Upon hypoxia, HIF1 is upregulated 
and HIF1 complexes bind to HREs transactivating hypoxia-inducible genes [65]. HIF1 has a unique 
domain sensitive to oxygen-dependant degradation. In normaxia, specific degradation of HIF1 is 
triggered through this domain by the proteasome [66]. Hypoxia is an important complication 
associated with lung diseases and tumors [72]. Reduced expression of HIF1 has been detected in the 
emphysema lung tissues in severe COPD patients [73], suggesting deregulation of HRE activities 
occurred in HIF1 targeting genes such as LO under this condition. Since cobalt chloride (CoCl2) 
stabilizes the HIF1 protein, this metal ion is used to mimic effects of hypoxia in cell study systems 
[74,75]. The MRE was initially found in multiple copies in metallothionein (MT) genes. MTs are 
cysteine-rich metal binding proteins essential for cellular metal metabolism and detoxification [68,69]. 
A protein that binds specifically to MREs is termed as MRE-binding transcription factor-1 (MTF-1) 
[67]. MTF-1 is a Zn finger transcription factor mediating the expression of MT genes which contain 
more copies of MREs. Cd and oxidative stress (such as H2O2) activate MTF-1 binding to the MT-I 
gene promoter by binding to or oxidation of other cellular protein sulfhydryls releasing bound Zn that Int. J. Environ. Res. Public Health 2011, 8          
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in turn enhances MTF-1 affinity for DNA, thus activating MRE containing genes [67]. The 
transcriptional factor interacted with the ARE is the NF-E2-related factor-2 (Nrf2) which drives 
expressions of a variety xenobiotic metabolizing enzymes such as GST, NQO1, UGT, GCL, HO-1, 
GSH synthetase, -glutamyl transpeptidase, etc., for antioxidant-detoxification [70]. Nrf2 is inactive in 
the cytoplasm by binding to the cysteine-rich Keap1 protein in the actin filaments. Upon oxidative 
stress, modification of cysteine residues in the Keap1 protein induces the Nrf2 release and nuclear 
translocation. After forming the heterodimer with Maf, Nrf2 binds to the ARE for transcriptional 
activation of the genes. CS exposure has been shown to generate reactive oxygen species (ROS) [16]. 
Transcription factors for the NFI binding site, HRE, MRE and ARE, are known sensitive to oxidative 
stress [62,66,69,70]. These redox-sensitive transcription factors will be addressed as potential targets 
for CS insult. A schematic linear map of the cloned rat LO promoter is shown in Figure 2. 
Figure 2. The schematic linear map of the cloned rat LO promoter. ATG, the translational 
start site; INR, the initiator element; DPE the down-stream core promoter element; NBS, 
the NFI binding site; HRE, the hypoxia response element; MRE, the metal response 
element; ARE, the antioxidant response element. 
 
 
4. LO as a Target of CS at Multiple Molecular Levels 
 
4.1. Inactivation of LO Catalytic Activity by CSC and Cd  
 
Previous studies by this lab have shown inhibition by CSC and Cd, major components of CS, of LO 
catalytic activity in treated cells [40,76,77]. LO is a metalloenzyme requiring Cu(II) as a cofactor for 
enzymatic function [41,55]. Dietary deprivation of Cu induced lathyritic injuries in animals due to 
suppression of LO activity [78-80]. It is known that thiol-containing MT is a critical modulator for Cu 
metabolism [81,82]. MT can chelate 11–12 moles of Cu/mole of protein [81] which are in the cuprous 
state [Cu(I)]. MT has a higher affinity for Cu than Cd since Cd selectively displaced Zn but not Cu in 
native calf liver MT, which binds four moles of Zn and three moles of Cu per mole of MT [83]. In 
addition to MT, glutathione (GSH) also functions in cellular Cu metabolism. GSH can form a complex 
with Cu-MT, providing the biological basis for Cu transfer between these two cellular thiols [82]. 
Reduction of Cu(II) to Cu(I) by GSH is thought to be a preliminary step in cellular transport of Cu. 
Cellular concentrations of GSH range from 0.1 to 10 mM, accounting for 90% of total cellular   
non-protein thiols. A rapid depletion followed by a later rebound increase of intra-cellular GSH was 
shown to occur in CS-treated lung cells and tissues consistent with marked increases of total GSH 
concentration in epithelial lining fluid (ELF) in cigarette smokers [84-87]. Our studies have illustrated Int. J. Environ. Res. Public Health 2011, 8          
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CSC and Cd enhancement of GSH levels in cultured lung cells and in lung tissues of the animal model, 
and upregulation of the catalytic unit of -glutamylcysteine synthetase (GCS), a rate-limiting enzyme 
for GSH synthesis, at protein and mRNA levels indicating the activation status of GSH biosynthesis 
under CSC and Cd stress conditions [40,76,88].  Markedly elevated levels of MT and GSH were 
associated with considerably decreased catalytic levels of LO in CSC or Cd-treated RFL6 lung 
fibroblasts [40,76,77]. In light of the function of MT and GSH in Cu metabolism, CSC or Cd-induced 
elevation of MT and GSH in treated cells may largely trap cellular Cu, thus limiting its biological 
availability for LO leading to downregulation of LO activity that requires Cu as a cofactor [40,76,77]. 
Notably, isotope labeling assays have demonstrated that in MT-overexpressing RFL6 cells following 
long-term Cd exposure, radioactivity of 
64Cu bound to the LO fraction amounted to only 9% of the 
control as compared to 1,400% of the control of 
64Cu associated with the MT fraction [77]. Direct 
correlation of elevated levels of cellular thiols with downregulation of LO in CSC or Cd treated cells 
came from experiments in which RFL6 cells were exposed to GSH monoethyl ester (GME), a GSH 
delivery system [40], or transfected with MT cDNA [88]. Clearly, elevation of cellular GSH and MT 
by these molecular approaches was associated with reduction of LO activity in cell conditioned media. 
These results provide evidence directly linking perturbation of the homeostasis of cellular thiol and 
copper to the reduction of LO catalytic activity in model cells in response to CSC or Cd.  
 
4.2. Inhibition of LO Protein Synthesis and Processing by CSC and Cd 
CSC and Cd reduced levels of all LO protein species including the 46 kDa preproenzyme,   
the 50 kDa proenzyme and the 32 kDa mature enzyme in cultured lung fibroblasts [40,76,77]. This 
may result from upstream mechanisms such as decreases in LO mRNA. Notably, a stronger inhibition 
of downstream LO species, i.e., the preproLO  the proLO  the mature LO, in cells treated with 
CSC under the same conditions, suggests that several steps in LO translational and posttranslational 
processing may be susceptible to CSC [40]. A major difference between Cd-resistant (CdR) RFL6 
cells derived from long-term Cd exposure and parental RFL6 cells is the presence of the variant   
52 kDa LO precursor in the former. The 52 kDa protein existed in the cell extract fraction but not the 
conditioned media, reflecting deficiency of secretion [76]. As revealed by double immunofluorescent 
staining, a number of large LO positive patches colocalized with the ER and nucleus structures in CdR 
cells, indicating an abnormal processing of LO precursor with its product accumulated in these 
organelles [76,77]. Since this variant LO precursor is apparently 2 kDa larger than the normal   
LO precursor, it may represent a molecular species without cleavage of the signal peptide, known to be 
a total of 21 amino acids in rat LO (Figure 1B). Another possibility to account for the variant   
LO proenzyme with a higher MW in CdR cells may be a different degree of N-glycosylation. It should 
be noted that the same 52 kDa protein recognized by the anti-LO antibody was also found in CdR-3T3 
cells derived from Swiss 3T3 fibroblasts using the same Cd exposure regimen [89]. These results 
suggest that the variant proenzyme derived from abnormal LO processing at translational and 
posttranslational levels may represent an important characteristic of long term Cd exposure.  Int. J. Environ. Res. Public Health 2011, 8          
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4.3. Downregulation of LO Transcription and Posttranscription by CSC/NNK and Cd 
Both CSC and Cd decreased the steady-state level of LO mRNA in treated cells [39,40,76]. The 
steady-state concentrations of mRNA as determined by Northern blot are dependent on both the 
transcriptional rate and the mRNA stability. CSC treatment induced decreased LO transcriptional rates 
as determined by the nuclear run-on assay and enhanced LO mRNA instability as illustrated by the 
actinomycin D chase assay [39]. The data further indicated that lower doses of CSC (<40 µg/mL) were 
sufficient to perturb the LO mRNA stability whereas higher doses of CSC (>80 µg/mL) were required 
to interfere with its transcriptional initiation. Thus, inhibition of the transcriptional rate and the mRNA 
stability both collectively contributed to decreased levels of steady-state LO transcripts in cells 
exposed to CSC.  
To further investigate CSC modulation of LO transcription, an approximately 4 kb genomic 
fragment spanning nucleotides from –3,979 to –1 (Prom –3,979) was inserted in front of the luciferase 
gene in the reporter gene vector. A series of 5’-deletions of the Prom -–3,979 indicated that the 
maximal luciferase activity was found in the 804 base pair region immediately upstream of ATG [59]. 
CSC significantly inhibited LO promoter-directed luciferase expression in treated cells consistent with 
its effects on the LO transcriptional initiation [39]. Redox-sensitive transcription factors such as NFI, 
HIF1, MTF-1, etc., are critical targets for CSC or Cd. CSC/NNK or Cd suppressed biological activities 
of the NFI binding sites, HRE, MRE except the ARE at the LO promoter region in interactions with 
corresponding transcription factors revealed by reporter gene activation, transcription factor cDNA 
expression and ChIP assays (Figures 3 and 4, and references [59,90,91]). At least two functional NFI 
binding sites (–594/–580 and –147/–133) are active in the 804 base pair promoter region of the LO 
gene. CSC inhibited NFI-binding site-directed luciferase activities in transfected cells in a   
dose-dependent manner and abolished the reporter gene activation by NFI A and B, two isoforms 
expressed in rat lung fibroblasts. The ChIP assays further confirmed CSC interferences with 
endogenous NFI incorporation with the LO gene in the RFL6 cell model [59,90]. Electrophoretic 
mobility shift, oligonucleotide competition and in vitro translation of HIF 1 assays indicated that only 
one HRE mapped at –387/–383 relative to the ATG was functionally active among 4 consensuses 
within the LO promoter region –804/–1 upstream of ATG. Cd enhanced cellular levels of reactive 
oxygen species (ROS) [92], thus inhibited HIF1 expression and binding to the LO gene in treated 
cells in the presence of CoCl2 (Co) that mimics hypoxia conditions in cell culture system revealed by 
ChIP and qPCR (Figure 3 and reference [91]). Cd significantly suppressed HIF1α mRNA expression 
in Cd-pulsed RFL6 cells and in Cd resistant cells stimulated by Co [91]. The cloned rat LO promoter 
(–804/–1 relative to ATG) also contains at least two MREs located at –269/–263 and –248/–241 and 
one ARE mapped at –581/–572. Unexpected, treatment of cells with Cd, a heavy metal, weakened but 
not enhanced MTF-1 binding to the MREs in the LO promoter thus inhibited LO mRNA expression 
(Figure 4A). Note that upregulation of MT as a major phenotypic change was accompanied by 
downregulation of LO in CSC or Cd treated cells [40,76] and both MT and LO promoters contain 
MREs. Different phenotype changes in LO and MT genes in response to Cd may be explained by that 
many MRE-related transcription factors would be recruited to bind to MREs in the MT promoters for 
gene activation thus competing with their binding to the LO promoter. As reported, MT-I and MT-II 
genes each contain six MREs in their promoter regions, respectively, which display the different Int. J. Environ. Res. Public Health 2011, 8          
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affinities for MTF-1 [67]. Apparently, LO MREs may have lower affinity than MT MREs for MTF-1 
binding. In contrast to the LO MREs in response to Cd, the LO ARE is activated in Cd treated cells as 
evidenced by enhancement of Nrf2 binding to the LO ARE as examined by the ChIP assay (Figure 
4B). Presumably, elevated ARE activities may play a critical role in maintaining the low basal level of 
the LO gene transcription under Cd stress conditions. NNK, a tobacco-specific carcinogen, is believed 
to contribute to the cancer burden in cigarette smokers [18]. Like Cd, NNK also inhibited activities of 
the LO MREs, but enhanced activities of the LO ARE (Figures 4A and 4B; reference [93]). NNK and 
Cd both have been shown to enhance methylation of CpG at the core promoter region of the LO gene 
(Figure 4E).  
Figure 3. Cd effects on HIF1 binding to the LO promoter HRE. RFL6 cells and   
Cd-resistant (CdR) cells derived from RFL6 cells by long-term Cd exposure were treated 
without or with Co to mimic the hypoxia condition in the cell culture system. Cells 
resistant to 20, 40, and 80 M Cd were referred to as CdR20, CdR40 and CdR80, 
respectively. HIF1 binding to the LO promoter HRE (–387/–383) in control and CdR 
cells were assessed by the ChIP assay (A) using RNA-Poly II binding to the GAPDH gene 
as an internal control (B) as described [59]. Primer pairs used in PCR are   
5’-ctccctgtgcaacgtgtct-3’ [forward (F)] and 5’-tgcagttacacaagccgttc-3’ [Reverse (R)]   
for amplification of the HRE containing LO gene fragment (152 bp), and   
5’-ttgcttggcttcttctttgg-3’ (F) and 5’-gagacgaggctggtactcca-3’ (R) for amplification of the 
GAPDH gene fragment (160 bp).  
 
Cytosine methylation in the CpG islands interferes with the interaction of DNA with proteins thus 
resulting in stable transcriptional repression [94,95]. Aberrant hypermethylation of genomic DNAs and 
increased levels of DNA methyltransferase (DNA MeTase) activity have been detected in NNK and 
Cd treated cells [22,23,96]. Furthermore, both NNK and Cd also suppressed histone H3 acetylation at 
the LO core promoter region (Figure 4C). The appropriate acetylation and deacetylation of H3 K56 is 
critical for chromatin assembly and genome stability [97]. Thus, inhibition of histone H3 acetylation is 
an important marker for inactivation of the LO gene by NNK and Cd. It should be noted that in Int. J. Environ. Res. Public Health 2011, 8          
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addition to its action on histone H3, LO also oxidizes histone H1, a substrate of LO [42,43]. Thus, LO 
may be a key factor for the modification of nuclear structure proteins relevant to changes in chromatin 
configuration. Cells long-term treated with CSC or -aminoproprionitrile (BAPN), that inhibits LO 
activity, exhibited an abnormal DNA organization manifested by appearance of nuclear blebs   
(Figure 5), the indices for chromosomal instability [98,99].  
Figure 4. NNK and Cd effects on MTF-1, Nrf2 and acetylated histone H3 binding to and 
methylation of the LO promoter. MTF-1 binding to the LO MRE (A), Nrf2 binding to the 
LO ARE (B) and acetylated histone H3 binding to the LO core promoter region (C) in 
RFL6 control, NNK (300 M for 48 h) and Cd (5 M for 24 h) treated cells, and in CdR 
cells were assessed by the ChIP assays as described [59] using RNA-Poly II binding to the 
GAPDH gene as an internal control (D). Methylation of the LO core promoter region (E) 
was assessed by using the promoter methylation PCR kit (Panomics, Fremont, CA., USA). 
Primer pairs used in PCR are 5’-cttcagacactgtgcgctct-3’ (F) and 5’-gcagggactggtgccaag-3’ 
(R) for amplification of the MTF-1-bound LO MRE fragment (150 bp);   
5’-tttggccctcatcgctct-3’ (F) and 5’-gacttaatctgggccgaaca-3’ (R) for amplification of the 
Nrf2-bound LO ARE fragment (162 bp); 5’-gaagaggtctccctccttcg-3’ (F) and   
5’-actgcagctgtcccagaaag-3’ (R) for amplification of the acetylated histone H3-bound LO 
core promoter (INR-DPE) region (136 bp); 5’-ttgcttggcttcttctttgg-3’ (F) and   
5’-gagacgaggctggtactcca-3’ (R) for amplification of the RNA Poly II-bound GAPDH gene 
fragment (160 bp); 5’-ttcagacactgtgcgctctc-3’ (F) and 5’-aggagggagacctcttcgag-3’ (R) for 
amplification of the methylated LO core promoter (INR-DPE) region (205 bp) containing 
15 CpG islands . 
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Figure 5. Alterations in nuclear organization in cells treated with CSC and BAPN, an 
inhibitor of LO. RFL6 cells were long-term incubated with graded concentrations of CSC 
from 80 to 160 g/mL. Survival cells isolated with different degrees of CSC-resistance 
(CSCR) such as to 80, 120 and 160 g/mL were referred to as CSCR80, CSCR120 and 
CSCR160. Arrows show altered nuclear morphology revealed by fluorescent DNA staining 
with propidium iodide. A, control; B, CSCR80; C, CSCR120; and D, CSCR160. 
Alterations in nuclear organization in RFL6 cells treated with BAPN, an LO inhibitor, at 
100  M for 7 days were revealed by histone H1 staining using the primary antibody 
against histone H1 and the secondary antibody conjugated with FITC. E, control; F, cells 
treated with BAPN. Asterisks show altered nuclear organization in BAPN-treated cells. 
Notably, both CSC and BAPN induced nuclear blebs. 
 
 
Thus, CSC, NNK and Cd, the major components of CS, perturbed LO at transcriptional, 
translational and catalytic levels representing a critical mechanism for CS toxicity to the lung   
(Figure 6).  
 
5. Downregulation of LO and Pathogenesis of the Lung 
 
5.1. LO Deficiency and Emphysema  
 
Lung ECM, a dynamic structure, is composed of a number of functionally diverse elements which 
are integrated mainly by interstitial cells, e.g., fibroblasts [100,101]. The overall pattern of the lung 
ECM results from an intricate balance between the synthesis and degradation of its major structural 
components, e.g., collagen and elastin. Thus, the pathogenesis of emphysema, a lung ECM disease, is 
initiated by multiple mechanisms as revealed by animal model studies [7]. CS induced emphysema in 
humans [102]. It has been established that CS-enhanced degradation of the lung ECM proteins resulted Int. J. Environ. Res. Public Health 2011, 8          
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from either the excess of protease production or the deficiency in 1-antitrypsin, an inhibitor of 
proteases, contributes to the onset of emphysema [7]. This review article aims at evaluation of the lung 
ECM protein synthesis and processing mechanism for emphysema pathology by emphasizing LO as a 
CS target. The critical role of LO in emphysema development was reflected in the disruption of the 
lung structure in chicks and rats following diet-induced deficiency of Cu, a cofactor for LO [78,79]. 
The lung lesions in these animals resembled panlobular emphysema in humans [80]. A mild form of 
emphysema was also produced in pigs raised on Cu deficient, Zn supplemented diet [103]. Zn, a 
known MT inducer, was used in this study based on its reported inhibitory effect on LO activity [104]. 
Figure 6. CS perturbs LO at transcriptional, translational and catalytic levels. At the 
promoter level, CS interferes with the interaction of redox-sensitive transcription factors 
such as NFI, HIF1, MTF-1 with corresponding cis-elements and induces methylation of 
CpG at the core promoter region inhibiting the initiation of LO gene transcription. At the 
mRNA levels, CS inhibition of both the synthesis and the stability of LO transcripts leads 
to decreased levels of steady-state LO mRNA. At the protein level, CS suppresses 
synthesis and processing of the preproLO such as signal peptide cleavage, and Cu binding 
to the proLO due to elevation of cellular thiols, resulting in reduction of the ProLO 
secretion to the ECM. At the catalytic levels mature apoLO without Cu cofactor binding 
exhibits the defect in enzyme activity. Thus, CS inhibition of the LO gene expression at 
multiple levels collectively contributes to decreased levels of the mature LO in the lung 
ECM favoring emphysema pathogenesis and carcinogenesis in the lung. 
 
 
Patients with Menkes disease, an X-linked recessive disorder of Cu transport associated with the 
deficiency in LO, developed severe diffuse emphysema leading to respiratory failure and early death 
[105]. BAPN, an irreversible inhibitor of LO, can limit the fibrogenic response in certain surgical 
procedures and decrease collagen/elastin deposition in models of lung fibrosis. Feeding of BAPN 
markedly enhanced elastase-induced emphysema in hamsters [106]. Moreover, with simultaneous Int. J. Environ. Res. Public Health 2011, 8          
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feeding of hamsters with BAPN, intratracheally instilled Cd resulted in lesions of emphysema but not 
fibrosis in the lung [107]. Additional evidence correlating LO deficiency with emphysema derives 
from studies of genetic variants of animals, e.g., blotchy mice with abnormal Cu transport, exhibited a 
deficiency of LO, inducing emphysema [108]. Furthermore, knockout mice deficient in LO, thus failed 
in crosslinking of collagen and elastin, resulted in major development problems in the lung manifested 
by emphysema [109]. Inactivation of LO and LO-like protein 1 individually caused enlarged airspaces 
of the lung [110,111]. It has long been known that cigarette smoke blocks cross-linking of elastin  
in vitro [112]. Our recent studies using CSC/NNK and Cd treated cells and Cd intratracheally instilled 
rats as in vitro and in vivo models have demonstrated downregulation of LO at multiple levels 
accompanied by inhibition of collagen and elastin expression in cell models and emphysema pathology 
in the lung of the animal model [40,76,88]. Modulation of the ECM gene expression by LO is 
supported by the observation that addition of BAPN, an inhibitor of LO, reduced mRNA levels of 
elastin in VSMC [113] and that overexpression of LO in COS-7 cells enhanced the promoter activity 
of the collagen type III gene [114]. 
 
5.2. LO Deficiency and Carcinogenesis in the Lung and Other Organs 
Suppression of a set of tumor suppressor genes is a prerequisite to prosecute CS oncogenic 
programs in the lung. LO is a tumor suppressor gene as evidenced by its inhibitory effects on ras 
transformation activities [52]. Consistent with the anti-tumorigenic function of LO, normal rat kidney 
fibroblasts became transformed by expression of LO antisense displaying anchorage-independent 
growth and elevation of p21-ras expression [115]. Low levels of LO mRNA were detected in a variety 
of spontaneous human cancers [116] such as lung bronchogenic carcinoma [117], gastric cancers [118], 
head and neck squamous cell carcinoma [119], etc. Reduced LO mRNA expression was detected in 
various lung cancer cells, one of which (VRMC-LCD) exhibited complete methylation of the LO 
promoter and loss of LO expression which was reversed upon treatment with 5-aza-dC [120]. LO 
mRNA expressions in human bronchogenic carcinomas displayed a 3.4-fold graded reduction as 
tumors progressed from Stage I to IV, with a similar pattern of downregulation in LO proteins [117]. 
Moreover, microarray analysis demonstrated decreased LO mRNA expression in primary lung 
adenocarcinoma tissues and lung cancer cell lines compared to normal lung tissues and lung cells 
[120]. LO transcripts were progressively reduced in malignant prostate tumors either at primary or at 
metastatic lesions [121]. In breast tumors abundant amount of LO was observed in benign breast 
lesions surrounding in situ ductal carcinomas and in reactive fibrosis at the invasion front of 
infiltrating tumors. The level of LO was markedly decreased in late stromal reactions and nodetectable 
in the loose scirrhous stroma of invading ductal carcinomas [122,123], but increased in   
hypoxia-induced metastasis of breast cancers [51]. LO was absent in basal and squamous cell 
carcinoma and its knockout induced an invading phenotype in a skin equivalent model [124]. The LO 
gene was inactivated by methylation and loss of heterozygosity in human gastric cancers [118]. 
Reduction of LO expression as a result of somatic mutation of the LO gene was associated with human 
colorectal tumors [125]. Our recent studies have demonstrated that purified mature LO suppressed the 
proliferation of transformed cells by inactivation of growth factors such as bFGF [44]. Repression of 
BCL2, a proto-oncogene, by proLO and LO propeptide inhibited transformed phenotype of lung cancer Int. J. Environ. Res. Public Health 2011, 8          
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cells (H1299) [120]. Moreover, LO modification of histone H1, H2 and H3, critical nuclear structural 
proteins, has been identified in vitro or in cells (Figure 4C, references [42,43,126]) and inhibition of 
LO enhanced chromatin instability (Figure 5). Therefore, modulating the expression of oncogenes such 
as ras and BCL2, regulating the activity of growth factors such as bFGF, and stabilizing nuclear 
proteins such as histone H1, H2 and H3 and thus maintaining chromatin and nuclear stabilities may be 
key mechanisms for LO tumor suppression. In view of novel functions of LO, downregulation of LO 
by CSC/NNK/Cd may severely impair its tumor suppressor properties triggering and facilitating 
carcinogenic programs in the lung. 
 
6. Conclusions 
 
In this paper, we have reviewed the literature for CS toxicity and our research findings, presented 
evidence for LO as a critical target for the insult of CSC, NNK and Cd, major components of CS, and 
emphasized the role of downregulation of LO, an enzyme with multiple biological functions, in the 
lung pathogenesis such emphysema and cancers. Further tracing CS effects on the interactions of LO 
with its substrates or binding ligands and exploring their underlying mechanisms are expected to 
provide the basis for prevention and treatment of CS-elicited lung diseases. 
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